Arecor Therapeutics plc
AREC.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.22 | 0.52 | -0.40 | -0.09 |
| FCF Yield | -37.34% | -10.72% | -16.02% | -5.99% |
| EV / EBITDA | -2.13 | -6.09 | -6.46 | -11.82 |
| Quality | ||||
| ROIC | -180.66% | -84.27% | -55.54% | -28.08% |
| Gross Margin | 30.54% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.86 | 0.68 | 1.02 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 28.11% | 58.06% | 12.28% | -15.08% |
| Free Cash Flow Growth | -53.17% | 46.14% | -101.58% | -189.11% |
| Safety | ||||
| Net Debt / EBITDA | 0.30 | 0.57 | 0.44 | 2.89 |
| Interest Coverage | -486.23 | -611.67 | -555.24 | -11.79 |
| Efficiency | ||||
| Inventory Turnover | 7.34 | 4.31 | 0.30 | 0.00 |
| Cash Conversion Cycle | 170.17 | 66.69 | -517.82 | 250.58 |